Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure.Wohlfarth P et al. Crit Care. 2014 Jan 20;18(1):R20. [Epub ahead of print].Clearance of Drugs for Multiple Myeloma Therapy During In Vitro High-Cutoff Hemodialysis.Krieter DH et al. Artif Organs. 2014 Jan 7. doi: 10.1111/aor.12248. [Epub ahead of print].Acupuncture for neuropathic pain due…
Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure.Zhou F et al. Leuk Lymphoma. 2014 Jan 28. [Epub ahead of print].Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?San Miguel JF. Haematologica. 2014 Jan;99(1):5-6. doi: 10.3324/haematol.2013.100982.Management of bone disease in multiple myeloma.Terpos E…
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. Palumbo A et al. J Clin Oncol. 2014 Jan 21. [Epub ahead of print]. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Merz M et…
This paper, written by an expert panel on behalf of the International Myeloma Working Group, outlines consensus recommendations for risk stratification for clinical and clinical trial use.
This paper, written by an expert panel of the International Myeloma Working Group, examines the impact of novel treatments on stem cell collection in myeloma patients. It summarises the available evidence and makes recommendations to address identified issues.